Globus Medical (NYSE:GMED) Given New $120.00 Price Target at Royal Bank Of Canada

Globus Medical (NYSE:GMED) had its price objective lifted by Royal Bank Of Canada from $115.00 to $120.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical device company’s stock.

Several other research analysts have also recently commented on the stock. Citigroup restated a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Piper Sandler restated an “overweight” rating and issued a $115.00 target price (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Wells Fargo & Company decreased their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Stock Down 8.5%

Shares of NYSE:GMED opened at $77.81 on Friday. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The firm has a 50-day simple moving average of $89.86 and a 200 day simple moving average of $86.65. The company has a market cap of $10.52 billion, a PE ratio of 18.10, a P/E/G ratio of 1.99 and a beta of 1.00.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.69%. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the prior year, the firm earned $0.68 EPS. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical will post 4.46 EPS for the current fiscal year.

Insider Buying and Selling at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. lifted its stake in Globus Medical by 12.5% during the first quarter. PNC Financial Services Group Inc. now owns 13,134 shares of the medical device company’s stock valued at $1,132,000 after purchasing an additional 1,455 shares during the last quarter. Convergence Investment Partners LLC acquired a new stake in Globus Medical during the first quarter valued at approximately $2,165,000. WCM Investment Management LLC purchased a new stake in shares of Globus Medical in the 1st quarter valued at approximately $16,965,000. Dimensional Fund Advisors LP lifted its position in shares of Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after acquiring an additional 33,976 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Globus Medical by 63.3% in the 1st quarter. Parallel Advisors LLC now owns 1,778 shares of the medical device company’s stock valued at $153,000 after acquiring an additional 689 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.